The negative group comprised patients of all ages, all histologies, and all grades of gliomas and was not associated with any definitive genetic signatures, whereas the other TMM groups were more likely to have certain genetic signatures, such as the combination of TERTp/IDH mutations and ATRX loss, and age distributions. The gene discussed is IDH2; the disease is central nervous system cancer.